Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other financing activities (2018 - 2025)

Heron Therapeutics (HRTX) has disclosed Other financing activities for 8 consecutive years, with -$47000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other financing activities fell 20.51% year-over-year to -$47000.0, compared with a TTM value of $160000.0 through Dec 2025, down 47.19%, and an annual FY2025 reading of $160000.0, down 47.19% over the prior year.
  • Other financing activities was -$47000.0 for Q4 2025 at Heron Therapeutics, up from -$51000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $4.2 million in Q2 2021 and bottomed at -$637000.0 in Q1 2022.
  • Average Other financing activities over 5 years is $147800.0, with a median of -$49000.0 recorded in 2025.
  • The sharpest move saw Other financing activities crashed 1850.0% in 2024, then surged 481.82% in 2025.
  • Year by year, Other financing activities stood at -$123000.0 in 2021, then plummeted by 74.8% to -$215000.0 in 2022, then skyrocketed by 99.07% to -$2000.0 in 2023, then plummeted by 1850.0% to -$39000.0 in 2024, then fell by 20.51% to -$47000.0 in 2025.
  • Business Quant data shows Other financing activities for HRTX at -$47000.0 in Q4 2025, -$51000.0 in Q3 2025, and $194000.0 in Q2 2025.